<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity dstore:dataset="ifcwbg-in" dstore:index="187" hierarchy="1" iati-activities:generated-datetime="2021-04-30T23:49:35" iati-activities:version="2.02" last-updated-datetime="2021-03-31T05:12:19" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-44289</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">RSE Glenmark</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Glenmark Pharmaceuticals Limited (Glenmark or the Company) is a global research-led pharmaceutical company with presence across generics, specialty, and OTC business with global presence in over 80 countries. Glenmarks key therapy focus areas are respiratory, dermatology and oncology. IFC committed an unsecured A loan of US$40 million to Glenmark on February 12, 2021 through an allocation under the IFC COVID-19 response facility to fund the Company&apos;s ongoing capital expenditure program in India and proposed refinancing of foreign currency debt maturities (Project).   In June 2016, IFC had invested in convertible debt of US$75 million in Glenmark to finance the Companys expansion project at the time, which has now been completed. The Project (2021 investment) is linked to Glenmark (#38371, 2016 investment):  https://disclosures.ifc.org/project-detail/SII/38371/glenmark</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN"></narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">GLENMARK PHARMACEUTICALS LIMITED</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-44289" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2020-07-09" type="1"></activity-date>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Glenmark Pharmaceuticals Limited  Kapil Kriplani  Vice President and Global Head - Treasury  +91 90046 55693  Kapil.Kriplani@glenmarkpharma.com  Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400099  www.glenmarkpharma.com</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN"></narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="IN" percentage="100">
   <narrative xml:lang="EN">India</narrative>
  </recipient-country>
  <location ref="IN-India">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">The Company has 16 manufacturing facilities globally, of which 12 are in India. Glenmarks formulation facilities are located in Indore, Aurangabad, Baddi, Sikkim, Goa, Nalagarh and Nashik and API facilities are located in Ankleshwar, Dahej, Kurkumbh &amp;Mohol.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>22.0000000000 79.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">other</narrative>
  </sector>
  <tag code="COVID-19" vocabulary="99"></tag>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $50.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetail/SII/44289">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetail/SII/44289">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
